About Speciality Medicines Ltd
Speciality Medicines are engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.
Founded
2021
CEO
Parth B Goyani
Employees
18
HQ
Mumbai, India
Finished Products
1Sale of Products
₹85.80CrRaw Materials
1Purchase of Stock-in-Trade
₹73.16CrAbout Speciality Medicines Ltd
Speciality Medicines are engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.
Founded:2021
CEO:Parth B Goyani
Employees:18
HQ:Mumbai, India
Finished Products
1Sale of Products
₹85.80CrRaw Materials
1Purchase of Stock-in-Trade
₹73.16CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹381
52W Low
₹121
Volume4.00K
Avg VolumeN/A
BetaN/A
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
10.18x
Valuation
P/B Ratio
1.86x
Valuation
EPS
₹14.83
Valuation
Dividend Yield
0.00%
Valuation
ROE
18.31%
Profitability
ROCE
18.42%
Profitability
Revenue by Segment
Contribution & growth by business line
No segment revenue data available
Geographical Revenue Split
Domestic vs international exposure
Domestic
0.0%
International
100.0%
Export sales69.1%
Domestic sales30.9%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.09x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
35.9%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.